20-F/A: Cordyceps Sunshine Biotech Restates 2023 Results, Shifts Focus

Cordyceps Sunshine Biotech Holdings Co., Ltd. filed an amended annual report for 2023, restating financial results and detailing a strategic spin-off of its Cordyceps business to focus on Cattle camphor mushroom products.

Summary

• The company filed Amendment No. 2 to its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, to clarify and correct operational results.
• On September 28, 2023, the company spun off its Cordyceps business (Cordyceps Sunshine HK and Chengdu Skyherb) by selling 100% equity interest to Mr. Xusheng Niu in exchange for cancelling a debt of $1,152,328.5.
• The company now specializes in cultivating and selling Cattle camphor mushroom raw materials and finished products.
• Total revenue for the year ended December 31, 2023, was $882,533, a significant increase from $53,304 in 2022.
• Net income from continuing operations was $169,285 in 2023, a turnaround from a net loss of $415,111 in 2022.
• Including discontinued operations and the gain from sale, the company reported a net income of $751,609 in 2023, compared to a net loss of $720,093 in 2022.
• As of December 31, 2023, the company had a negative working capital of $2,638,968 and an accumulated deficit of $472,966.
• The auditor raised substantial doubt about the company's ability to continue as a going concern.
• Management identified material weaknesses in internal control over financial reporting due to a lack of sufficient U.S. GAAP and SEC reporting personnel and comprehensive accounting policies.

Sentiment

Score: 5

Explanation: While the company reported a significant increase in revenue and a return to net income from continuing operations, along with a strategic spin-off, the auditor's going concern warning, substantial accumulated deficit, negative working capital, and identified material weaknesses in internal controls present considerable risks. The future success hinges on securing additional financing and effectively addressing these operational and financial challenges.

Positives

• Total revenue increased significantly to $882,533 in 2023 from $53,304 in 2022, representing a 1555.66% increase.
• Net income from continuing operations reached $169,285 in 2023, a substantial turnaround from a net loss of $415,111 in 2022.
• The company achieved an overall net income of $751,609 in 2023, reversing a $720,093 net loss in 2022.
• A gain of $865,085 was realized from the sale of the discontinued Cordyceps operations.
• Net cash provided by operating activities was $359,724 in 2023, a positive shift from negative operating cash flows in prior years.
• The company is actively cultivating its own Cattle camphor mushroom raw materials and expects to harvest in 2025, aiming to become a primary source.
• Possesses patented cultivation technology for Cattle camphor mushroom, which is expected to reduce cultivation costs and increase production capacity.
• Plans to expand product offerings with diversified Cattle camphor mushroom specialty items and establish an online presence in key international markets.

Negatives

• The auditor raised substantial doubt about the company's ability to continue as a going concern due to recurring net losses, a significant accumulated deficit of $472,966 as of December 31, 2023, and negative operating cash flows in prior years.
• The company reported a negative working capital of $2,638,968 as of December 31, 2023.
• Material weaknesses were identified in internal control over financial reporting, specifically a lack of sufficient U.S. GAAP and SEC reporting personnel and comprehensive accounting policies.
• Heavy reliance on a single major customer, accounting for 14.37% of revenue in 2023 and 100% in 2022, and a single major supplier, accounting for 100% of purchases in 2023 and 2022.
• The company does not carry business interruption, product recall, or third-party liability insurance for its production facilities or products.
• Ownership and voting power are highly concentrated, with Mr. Szu Hao Huang and Mr. Yenhung Liu indirectly owning approximately 59.3% of ordinary shares.
• There is no public market for the company's ordinary shares, and they may be designated as a penny stock, limiting marketability.
• The company has a limited operating history in its current business focus on Cattle camphor mushroom.

Risks

• The company is subject to export regulations in Taiwan, and any adverse regulatory action may materially adversely affect financial condition and business operations.
• Instability in international markets or foreign currency fluctuations could adversely affect results of operations.
• Dependence on single-source suppliers for some products could lead to delays or interruptions in product delivery.
• New laws and regulations affecting the business could delay or cease marketing and sales activities or impose additional costs.
• Selling and distributing all products outside the U.S. exposes the company to risks of international business, including economic downturns and political instability.
• Significant legal and other obstacles exist for shareholder investigations or litigation outside China, limiting legal protection.
• Uncertainty regarding the enforcement of laws and the risk of rapid changes in Chinese rules and regulations could limit legal protection.
• The Chinese government may intervene or influence operations at any time, potentially limiting the ability to offer securities or causing their value to decline.
• PRC regulation of loans and direct investment by offshore holding companies in PRC entities may delay or prevent capital contributions.
• Failure by PRC resident stockholders or beneficial owners to comply with foreign exchange regulations could restrict profit distribution or investment activities.
• Exposure to liabilities under the U.S. Foreign Corrupt Practices Act (FCPA) and Chinese anti-corruption law.
• Potential scrutiny, criticism, and negative publicity involving U.S.-listed Chinese companies could harm business operations and reputation.
• Uncertainty regarding oversight by the Cyberspace Administration of China (CAC) and its potential impact on business operations.
• Ordinary shares may be prohibited from trading on the OTC Markets due to the Holding Foreign Companies Accountable Act (HFCAA).
• Approval from the China Securities Regulatory Commission (CSRC) or other PRC regulatory agencies may be required for offerings under PRC law.
• Current business is significantly based on a few products (Cattle camphor mushroom), and failure of these products could materially impact revenue.
• Inability to grow and harvest sufficient Cattle camphor mushroom could disrupt production and adversely affect financial condition.
• Future changes in regulations on Cattle camphor mushroom in Taiwan could adversely affect operations.
• Sales and reputation may be affected by product liability claims, product recalls, pests contamination risks, or adverse publicity.
• Inability to establish and maintain brand name recognition could negatively impact sales.
• Expansion of business may put pressure on management and operational infrastructure, impeding ability to meet increased demand.
• Past results may not be indicative of future performance, making business and prospects difficult to evaluate.
• Dependence on key personnel, and turnover of key employees and management could harm the business.
• Reliance on a limited number of key clients creates significant client and industry concentration risk.
• Substantial additional funding is required for the company's ability to continue as a going concern, with no assurance of availability.
• Inability to protect intellectual property may prevent successful marketing and effective competition.
• Lack of business interruption or third-party liability insurance for production facilities exposes the company to significant financial losses.
• The highly concentrated ownership and voting power may impact shareholders' interests.
• Increased costs will be incurred as a public company, particularly after ceasing to qualify as an emerging growth company.
• Ordinary shares may be considered a penny stock, subject to restrictions on marketability.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports or fraud.
• The market price for the ordinary shares may be volatile.
• Future sales or issuances of substantial amounts of ordinary shares could adversely affect the share price.
• Limited shareholder protections against interested director transactions and conflicts of interest due to non-compliance with certain corporate governance measures.
• Ordinary shares represent equity interests and are subordinate to existing and future indebtedness.

Future Outlook

The company expects its main growth in 2024 to come from product sales in Taiwan and anticipates strengthening demand for its products and services, which should generate more positive cash flow. It plans to expand product offerings with diversified Cattle camphor mushroom specialty items and establish an online presence in Hong Kong, China, Japan, and the United States. The company also aims to deepen collaboration with raw material agents, health food manufacturers, and biotech pharmaceutical companies. It expects to harvest its own cultivated Cattle camphor mushroom in 2025, becoming a primary source of raw materials. To meet future funding requirements, the company plans to obtain capital from management and seek third-party equity and/or debt financing.

Management Comments

• Management cannot provide any assurances that we will be successful in accomplishing any of our plans to obtain additional capital resources.
• We believe we can satisfy our cash requirements so long as it is able to obtain financing from these affiliated parties.

Industry Context

The company operates in the traditional Chinese medicinal herb and dietary supplement industry, focusing on Cattle camphor mushroom, a unique and prized medicinal fungus indigenous to Taiwan. The Taiwanese government has supported research in this sector, recognizing its significance alongside Korean ginseng and Chinese Cordyceps. Global demand for Cattle camphor mushroom is growing due to increased awareness of traditional Chinese medicine, leading to overharvesting of wild stocks and supply shortages. The Chinese domestic market demand for Cattle camphor mushroom was 2812.13 tons in 2023, projected to reach 4341.34 tons by 2027, with an annual growth rate of 9-12%, indicating a substantial market opportunity. The company's patented cultivation technology aims to address the supply gap and high costs associated with traditional methods. The company previously operated in the Cordyceps market, which also experiences high demand and supply shortages globally.

Comparison to Industry Standards

• The significance of the Cattle camphor mushroom industry in Taiwan parallels that of Korean ginseng and Chinese Cordyceps, indicating its high value within traditional medicinal markets.
• Our harvested Cattle camphor mushroom exhibits potency comparable to that of wild-grown Cattle camphor mushroom, suggesting a high-quality product despite being cultivated.
• Our cultivation technology reduced cultivation costs, increased production capacity, and the ability to be reused, positioning the company to fill the market demand gap more efficiently than traditional methods.
• The Chinese domestic market demand for Cattle camphor mushroom was 2812.13 tons in 2023 and is expected to reach 4341.34 tons by 2027, with an annual growth rate of 9-12%, highlighting a significant market opportunity that the company aims to address with its cultivation methods.

Corporate Governance

Related Party Transactions

• Sales to Gasar Biotechnology Co., Ltd. (a company managed by Mr. Szuhao Huang) amounted to $126,856 in 2023 (14.37% of revenue) and $53,304 in 2022 (100% of revenue).
• Amounts due to Mr. Szuhao Huang (Director, CEO, CFO) were $36,302 as of December 31, 2023, for working capital purposes, payable on demand, and non-interest bearing.
• The company entered into an exclusive licensing agreement with Mr. Yen Hung Liu (Director) on February 5, 2024, for six cultivation technologies, with licensing fees to be paid.
• The spin-off of Cordyceps Sunshine HK and Chengdu Skyherb to Mr. Xusheng Niu on September 28, 2023, was in exchange for cancelling a $1,152,328.5 debt, which originated from loan agreements between the company and Mr. Niu.
• The company plans to satisfy its cash requirements for the next 12 months through borrowings from related parties, including Mr. Szuhao Huang, Mr. Yenhung Liu, and Gasar Biotechnology Co., Ltd.

Stakeholder Impact

• Shareholders face potential dilution if additional equity is raised and have limited influence due to highly concentrated ownership.
• Shareholders are exposed to market price volatility and limited protections due to the absence of certain corporate governance measures.
• Employees may experience increased operating costs due to competition for qualified personnel, impacting compensation.
• Customers face potential risks from product liability claims, recalls, or adverse publicity, which could affect product demand and the company's reputation.
• The company's dependence on a single major supplier creates a risk of supply chain disruption, potentially impacting product availability.
• Creditors face risks related to the company's going concern warning and negative working capital, raising doubts about its ability to meet liabilities, although existing long-term loans are from individuals.

Next Steps

• Obtain additional capital from management, principal stockholders, and private placement.
• Seek third-party equity and/or debt financing.
• Implement measures to improve internal control over financial reporting, including engaging experienced financial consultants, providing U.S. GAAP training, and improving financial oversight.
• Expand product offerings with diversified Cattle camphor mushroom specialty items.
• Establish an online presence in Hong Kong, China, Japan, and the United States through e-commerce platforms.
• Deepen collaboration with raw material agents, health food manufacturers, and biotech pharmaceutical companies.
• Harvest own cultivated Cattle camphor mushroom in 2025.

Key Dates

Recommendation

Despite a reported net income and revenue growth in continuing operations, the company faces severe fundamental challenges. The auditor's 'going concern' warning, substantial accumulated deficit, and negative working capital indicate significant financial instability. The identified material weaknesses in internal controls over financial reporting suggest unreliable financial reporting. Furthermore, heavy reliance on a single customer and supplier, coupled with the lack of critical insurance, exposes the company to high operational risks. While the strategic shift to Cattle camphor mushroom and patented technology offer potential, the immediate financial health and governance issues outweigh these prospects, making the stock a high-risk investment with significant downside potential.

Keywords

Cattle camphor mushroom, Taiwanofungus, Biotech, Dietary supplements, SEC filing, Form 20-F/A, Financial restatement, Going concern, Corporate governance, Risk factors, Taiwan, Herbal products, Cultivation technology, Financial reporting, Spin-off, Traditional Chinese medicine